Predictive Clinical Development: Accelerating Success From Design to Delivery

Clinical development programs now take 2 years longer than they did a decade ago, yet many delays are predictable and preventable. Join us to explore how sponsors can accelerate critical decisions, reduce development "white space," and achieve faster, more predictable clinical development through a connected approach to design, execution , and delivery

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/predictive-clinical

Event overview:

Clinical development programs now take 2 years longer than they did a decade ago, as increasing complexity, protocol amendments, regulatory demands, and recruitment challenges continue to slow progress. This webinar explores practical approaches that can help sponsors identify risks earlier, make more informed development decisions, reduce delays both within and between trials, and improve execution across the development lifecycle.

Learn how early engagement, real-world evidence, AI-enabled intelligence, and integrated delivery models can help transform clinical development from a reactive process into a more predictive, connected, and accelerated pathway to patients.

Key Learning Objectives

• A framework for identifying the decisions, risks, and inefficiencies that most commonly delay clinical development
• An understanding of how early engagement, real-world evidence, and AI-enabled intelligence can accelerate critical development decisions and improve confidence in the chosen path forward
• Practical insights into how sponsors can reduce development "white space," improve execution predictability, and bring therapies to patients faster

Speakers:

Brian O'Dwyer
President, Global Clinical Development — IQVIA

Brian O'Dwyer is the president of global clinical development, which comprises Clinical Operations (both Full Service Core and Functional Service Provider Operations), IQVIA Biotech, Patient & Site Centric Solutions, and Clinical Trial Supplies. In this role, he is accountable for over 25,000 staff. Previously, O'Dwyer was chief executive officer of IQVIA Laboratories for 7 years, where he was responsible for strategic goals, accelerating growth, and ensuring high-quality delivery of lab services to customers.

O'Dwyer has more than 27 years of experience in the health care and laboratory industry and has broad experience in the establishment, management, integration, and restructuring of both business and commercial operations across the clinical research spectrum. Prior to IQVIA, O'Dwyer served as senior vice president of the Eurofins Scientific Central Laboratory business. He also was senior vice president of Global Bioanalytical Services at ICON, having previously led ICON's Early Phase Clinical division in Europe and served as their group financial controller. O'Dwyer holds a bachelor's degree in business studies from Dublin City University, Ireland, and is a professionally certified management accountant.

Cynthia Verst, PharmD, MS
President, Design and Delivery Innovation — IQVIA

Cynthia Verst is president, design and delivery innovation, research and development solutions, at IQVIA. In this role, Verst is responsible for driving innovation and transformation throughout the clinical development trial life cycle. She leads the global, integrated Applied Data Science Center, Therapeutic Science and Strategy Unit, and Regulatory Affairs and Drug Development Solutions. Having previously served as president of both clinical operations and real-world and late phase research for IQVIA, Verst brings a holistic and comprehensive view of clinical research and champions the advanced use of real-world data, analytics, and technology to advance new therapies for patients. Recognized as a top woman in biotech by FierceBiotech and as a PharmaVoice Top 100 leader, she currently sits on the board of directors for ACRO. She is also the past chair of the DIA Board of Directors and is a member of the DIA Fellows.

Prior to joining IQVIA (then Quintiles), she served as senior vice president, global late phase research, for OptumInsight (a division of UnitedHealth Group). Verst began her career in biopharma at Procter & Gamble Pharmaceuticals as section head in its North American Medical and Technical Affairs group.

Verst holds a doctorate and bachelor's degree in pharmacy from the University of Cincinnati, a master's degree in structural and cellular biology from the University of Illinois, and bachelor's degrees in biology and chemistry from Northern Kentucky University.

Kenneth Getz, MBA
Director and Professor — Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Ken Getz is the executive director of the Tufts Center for the Study of Drug Development and a research professor at the Tufts University School of Medicine. He is an internationally recognized expert on pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage, and patient engagement. A well-known speaker at conferences, symposia, universities, investor meetings, and corporations, Getz has published extensively in peer-reviewed journals, books, and in the trade press. He holds a number of board appointments in the private and public sectors. He received his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and his bachelor's degree from Brandeis University. Getz is also the chairman of CISCRP, a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise, and the founder of CenterWatch, a leading publisher in the clinical trials industry.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/predictive-clinical